Alexion's $550,000 bone drug too expensive for Britain

LONDON (Reuters) - A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more than $550,000 a year for each patient has been deemed too expensive by Britain's health cost watchdog NICE.

http://ift.tt/1Tm3yq1

from Reuters: Health News
via IFTTT